Base Genomics, a company specialising in epigenetics, has recently launched with a team of leading scientists and clinicians. Their goal is to establish a new standard in DNA methylation detection.
The company has completed an oversubscribed seed funding round of $11 million to develop its TAPS technology further. Initially, they will be focusing on creating a blood test for early-stage cancer and minimal residual disease. The funding round was spearheaded by Oxford Sciences Innovation and included investors with industry expertise in genomics and oncology.
Base Genomics is led by a highly experienced team of scientists and clinicians. This team includes Dr Vincent Smith, a renowned expert in genomic product development and former Illumina VP; Dr Anna Schuh, Head of Molecular Diagnostics at the University of Oxford and Principal Investigator on over 30 clinical trials; Dr Chunxiao Song and Dr Yibin Liu, co-inventors of TAPS at the Ludwig Institute for Cancer Research, Oxford; and Oliver Waterhouse, previously an Entrepreneur in Residence at Oxford Sciences Innovation and founding team member at Zinc VC.